Bioassay

Comparison of three methods for detecting dsRNA residues in mRNA vaccines*

Expand
  • National Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing 102629, China

Received date: 2022-06-28

  Online published: 2024-06-25

Abstract

Objective: To provide technical support for mRNA vaccine quality control by compareing with 3 methods of homogeneous time resolved fluorescence(HTRF),enzyme linked immunosorbent assay(ELISA) and Dot Blot for detecting dsRNA residues. Methods: According to the characteristics of HTRF,ELISA and Dot Blot assay respectively, the standards with different concentration were prepared and the dsRNA residues of samples were calculated by the standard curve. And tests were investigated in applicability, accuracy, precision, limit of quantitation and non-linear response. Results: The HTRF method showed that the recovery was 110.7% with the RSD of repeatability and intermediate precision were 5.6% and ≤19.0% respectively, the non-linear range of dsRNA fell into 1.56-100.00 ng·mL-1(r=0.999 3). The ELISA method showed that the recovery was 103.2% with the RSD of repeatability and intermediate precision were 19.5% and ≤11.7% respectively, the non-linear range of dsRNA fell into 7.81-500.00 ng·mL-1(r=0.999 8). The Dot Blot method showed that the recovery was 101.5% with the RSD of repeatability and intermediate precision were 18.5% and ≤42.2% respectively, the non-linear range of dsRNA fell into 800.00-80 000.00 ng·mL-1(r=0.999 2). The accuracy and precision of the HTRF and ELISA method are effective, and the HTRF method could detect lower concentrations of dsRNA residues. Conclusion: The three methods all could determine the dsRNA residues in mRNA vaccines effectively.

Cite this article

LIU Jing-jing, LI Yu-hua . Comparison of three methods for detecting dsRNA residues in mRNA vaccines*[J]. Chinese Journal of Pharmaceutical Analysis, 2022 , 42(11) : 1941 -1946 . DOI: 10.16155/j.0254-1793.2022.11.10

References

[1] JUNO JA, TAN HX, LEE WS, et al. Humoral and circulatingfollicular helper T-cell responses in recovered patients with COVID-19[J].Nat Med, 2020, 26(9): 1428
[2] GILBER PB, MONTEFIORI DC, McDERMOTT AB, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial[J].Science, 2022, 375(6576): 43
[3] MOREIRA ED, KITCHIN N, XU X, et al. Safety and efficacy of a third dose of BNT162b2 COVID-19 cvaccine[J].N Engl J Med, 2022, 386(20): 1910
[4] KARIKO K, MURAMATSU H, LUDWIG J, et al. Generating the optimal mRNA for therapy: HPLC purification eliminates immuneactivation and improves translation of nucleoside-modified, protein-encoding mRNA[J].Nucleic Acids Res, 2011, 39(21): e142
[5] PARDI N, HOGEN MJ, PORTER FW, et al. mRNA vaccines——a new era in vaccinology[J].Nat Rev Drug Discov, 2018, 17(4):261
[6] Assessment Report: COVID-19 Vaccine Moderna[DB/OL]. (2021-01-20)[2022-06-09]. https://www.ema.europa.eu/en/documents/assessment-report/spikevax-previously-covid-19-vaccine-moderna-epar-public-assessment-report_en.pdf
[7] Assessment Report: Comirnaty[DB/OL]. (2020-12-23)[2022-06-09]. https://www.ema.europa.eu/en/documents/assessment-report/comirnaty-epar-public-assessment-report_en.pdf
[8] SUN H. Double-stranded RNA sensors and modulators in innateimmunity[J].Annu Rev Immunol, 2019, 37:349
[9] 国家药品监督管理局药品审评中心. 《新型冠状病毒预防用mRNA疫苗药学研究技术指导原则(试行)》[EB/OL]. (2020-08-14)[2022-04-05].https://www.cde.org.cn/zdyz/domesticinfopage?zdyzIdCODE=9efa70b504dc5c66965001181a49c30b
Center for Drug Evaluation. Guideline on the use of pharmacodynamics in the development of prophylactic mRNA vaccines against COVID-19 (for trial implementation)[EB/OL]. (2020-08-14)[2022-04-05]. https://www.cde.org.cn/zdyz/domesticinfopage?zdyzIdCODE=9efa70b504dc5c66965001181a49c30b.
[10] SCHNEIDER WM, CHEVILLOTTE MD, RICE CM. Interferon-stimulatedgenes: a complex web of host defenses[J].Annu Rev Immunol, 2014, 32: 513
[11] MUSSABEKOVA A, DAEFFLER L, IMLER JL. Innate and intrinsicantiviral immunity in Drosophila[J].Cell Mol Life Sci, 2017, 74(11): 2039
[12] GARGANO JW, WALLACE M, HADLER SC, et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the Advisory Committee on Immunization Practices-United States, June 2021[C].MMWR Morb Mortal Wkly Rep, 2021, 70(27): 977
[13] DIAZ GA, PARSONS GT, GERING SK, et al. Myocarditis and pericarditis after vaccination for COVID-19[J].JAMA, 2021, 326(12): 1210
[14] SCHÖNBORN J, OBERSTRASS J, BREYEL E, et al. Monoclonal antibodies to double-stranded RNA as probes of RNA structure in crude nucleic acid extracts[J].Nucl Acids Res,1991, 19(11): 2993
[15] SCHWEINOCH D, BACHMANN P, CLAUSZNITZERER D, et al. Mechanistic modeling explains the dsRNA length-dependent activation of the RIG-I mediated immune response[J].J Theor Biol, 2020, 500:110336
Outlines

/